ArticleActa neurochirurgica2023
Recurrence of brain arteriovenous malformations in pediatric patients: a long-term follow-up study.
Article in Acta neurochirurgica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Management of pediatric brain arteriovenous malformation: a systematic review of retrospective studies.Neurosurgical review · 2026Pooled it
- Perioperative outcomes and risk stratification following pediatric arteriovenous malformation resection: an ACS NSQIP-P database analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Beyond Resection: Determinants of Outcome After Pediatric Brain Arteriovenous Malformation Surgery.Medicina (Kaunas, Lithuania) · 2026Article
- Review
- Cure or coincidence? The need for long-term rigor in pediatric arteriovenous malformation radiosurgery.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Cirrhosis-associated intracranial shunting lesions: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Recurrence of Angiographically Cured AVMs: Influence of Age, Angioarchitecture, and Hemorrhagic Presentation and Implications for Follow-Up.Stroke (Hoboken, N.J.) · 2026Article
- Arteriovenous Malformations (AVMs): Molecular Pathogenesis, Clinical Features, and Emerging Therapeutic Strategies.Biomolecules · 2025Review
- Advances in the Multimodal Management of Pediatric Arteriovenous Malformations: A 10-Year Review.Life (Basel, Switzerland) · 2025Review
- Pediatric cerebral arteriovenous malformation diagnosed 11 years after neonatal thalamic hemorrhage: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- High-Flow Congenital Arteriovenous Malformation of the Right Deltoid Muscle in a Pediatric Patient: A Case Report.Cureus · 2025Article
- Long-term outcomes in pediatric brain AVMs: beyond radiological cure.Brain & spine · 2025Article
- One-stop hybrid operation versus microsurgery for treating brain arteriovenous malformation in children-a retrospective case series.Translational pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreviously thought to be congenital, AVMs have shown evidence of de-novo formation and continued growth, thus shifting thoughts on their pathophysiology. Pediatric AVM patients have been reported to be more prone to develop AVM recurrence after a seemingly complete cure. Therefore, we assessed the risk of AVM treated in childhood to recur in adulthood after a long-term follow-up in our own cohort.
methodsControl DS-angiography was arranged during 2021-2022 as part of a new protocol for all AVM patients who were under 21 years of age at the time of their treatment and in whom the treatment had occurred at least five years earlier. Angiography was offered only to patients under 50 years of age at the time of the new protocol. The complete eradication of AVM after the primary treatment had been originally confirmed with DSA in every patient.
resultsA total of 42 patients participated in the late DSA control, and 41 of them were included in this analysis after excluding the patient diagnosed with HHT. The median age at the time of admission for AVM treatment was 14.6 (IQR 12-19, range 7-21 years) years. The median age at the time of the late follow-up DSA was 33.8 years (IQR 29.8-38.6, range 19.4-47.9 years). Two recurrent sporadic AVMs and one recurrent AVM in a patient with hereditary hemorrhagic telangiectasia (HHT) were detected. The recurrence rate was 4.9% for sporadic AVMs and 7.1% if HHT-AVM was included. All the recurrent AVMs had originally bled and been treated microsurgically. The patients with sporadic AVM recurrence had been smoking their whole adult lives.
conclusionsPediatric and adolescent patients are prone to develop recurrent AVMs, even after complete AVM obliteration verified by angiography. Therefore, imaging follow-up is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.